Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5912839 | 0.88 | MAPT (0.50) | PDE3BPDE3AEGFRSRCMAPT | |
| SCHEMBL6031474 | 0.83 | EGFR (0.50) | PDE3BPDE3AEGFRKDRKMT2A | |
| SCHEMBL22049240 | 0.81 | CYP3A4 (0.52) | PDE3BPDE3AEGFRSRCCYP3A4 | |
| SCHEMBL6881236 | 0.80 | PDE3B (0.45) | PDE3BPDE3A | |
| SCHEMBL3280903 | 0.77 | TSHR (0.47) | SRCMAPK1ALDH1A1GAATSHR | |
| SCHEMBL293099 | 0.76 | PDE3B (0.77) | PDE3BPDE3ASRCALDH1A1ACHE | |
| SCHEMBL15427070 | 0.75 | PDE3B (0.45) | PDE3BPDE3AMAPTALDH1A1GAA | |
| SCHEMBL578508 | 0.74 | SRC (0.57) | PDE3BPDE3AEGFRSRCCYP3A4 | |
| SCHEMBL16339494 | 0.73 | CYP11B1 (0.57) | PDE3BPDE3AEGFRSRCCYP3A4 | |
| SCHEMBL28982482 | 0.71 | SRC (0.51) | EGFRSRCCYP3A4MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101878203-A | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents | NATCO PHARMA LTD | 2010-11-03 | — | — | CN | claimed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | claimed |
| EP-2220054-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | Natco Pharma Limited (IN) | 2010-08-25 | — | — | EP | claimed |
| WO-2009057139-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | PDE3B 2359/4885PDE3A 2496/4885EGFR 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.